Compare Bilibili Inc (BILI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bilibili Inc vs Merck & Co., Inc. — how do they compare? Bilibili Inc trades at $17.49 (market cap $7.65B), while Merck & Co., Inc. trades at $132.76 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 42.1× Bilibili Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.
| BILI | MRK | |
|---|---|---|
Market Cap | $7.65B | $321.77B |
Sector | Media | Health |
52-Week High | $35.92 | $131.84 |
52-Week Low | $15.96 | $77.60 |
Enterprise Value | $5.49B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $17.48, down 7.95% over 24 hours, reflecting bearish technical momentum. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.19 versus $0.17 expected, and revenue growth to $30.35 billion in 2025. Analyst sentiment remains overwhelmingly bullish with 20 buy ratings out of 24, supported by a $300 million share repurchase program announced June 24, 2026.
The outlook is positive given robust user engagement and advertising growth, but risks include competitive pressures and reliance on Chinese market dynamics. Valuation metrics like a P/E of 36.24 suggest premium pricing, requiring sustained execution to justify upside. Near-term focus is on Q2 2026 earnings due August 27, 2026, which could catalyze movement.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
